Sanjay Dubé

Former head of clinical development and scientific strategy at Avanir Pharmaceuticals (Otsuka Pharma). Lead for several late and early-stage drug candidates at Theravance and Eli Lilly. Distinguished Fellow of the APA and Adjunct Professor, Dept. of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. Received his medical degree (M.B; B.S) and M.D (honors) in Psychiatry at King George’s Medical University, India, and subsequently at Wayne State and University of Pittsburgh. Expertise in mood and anxiety disorders and treatment resistant depression (approval of SYMBYAX ®), schizophrenia, neurodegenerative disorders (Alzheimer’s disease, ALS, Parkinson’s, PBA), traumatic brain injury and other neuropsychiatric disorders.